Menopause care in Canada is stretched thin. Here’s where that leaves you and where we’ve decided to stand.

On July 9, Medscape News Canada ran a piece with a headline any of our members could’ve written: “Lack of Menopause Care in Canada Reflects Systemic Issues.” Dr. Nicolas Leyland, president of the Society of Obstetricians and Gynecologists of Canada, described a system stuck for lack of enough primary care providers or trained clinicians to meet demand, and called for mandatory menopause training, group counselling models, and a shift toward compensation that rewards education over volume. Dr. Jen Gunter, also quoted in the piece, put it plainly: a family doctor in Ontario can get a billing code for sports medicine more easily than one for menopause care. That, she said, tells you everything.

That’s the professional body talking, not a members’ forum vent.

What this actually looks like, right now, in one province

I live in British Columbia, so I’m watching this from close range, and it’s worth saying plainly: there’s more happening here than just the one clinic.

In July 2025, BC Women’s Hospital opened the Complex Menopause Clinic, the first of its kind in Western Canada, designed specifically for people whose symptoms couldn’t be managed elsewhere. That was a real step forward. About 85% of people going through menopause deal with symptoms that make daily life harder, think hot flashes, poor sleep, mood swings, or aching joints. BC started covering hormone therapy for free in March 2026 (BC government news release, 2025).

It’s not the only thing underway. The Women’s Health Research Institute spent the past year running Mapping Menopause, bringing together clinicians, researchers, and people with lived experience from across the province to set concrete research priorities rather than guessing. The report came out in June 2026 and lays out the top ten priorities for BC (Brotto et al., Women’s Health Research Institute, 2026). Alongside it, WHRI, Pacific Blue Cross, and the BC Women’s Health Foundation ran the HER-BC study, examining how the transition affects work, caregiving, and quality of life, not just symptoms in isolation. BC Women’s Hospital, WHRI, and the Foundation also run a free public webinar series roughly every two months, with clinicians like Dr. Jen Gunter, Dr. Lori Brotto, and Dr. Kelsey Mills covering hormone therapy, genitourinary symptoms, and the mood and brain effects of the transition (BC Women’s Hospital, menopause resources).

Here’s the number that puts it in perspective: by the BC Women’s Health Foundation’s own count, one in three women in BC are in menopause right now (BC Women’s Health Foundation, 2026). Against that, the Complex Menopause Clinic delivered approximately 150 care appointments in its first year. That’s not a knock on the clinic, which is doing exactly what it was built to do, triaging the most complex cases first. It’s just the actual shape of the gap: a genuine start against a need that far exceeds it. The Foundation says as much itself, their full vision of integrated clinical care, research, and education is still being fundraised, not finished.

What it does to you while you’re waiting

The clinical facts matter, but so does what the wait actually feels like, and there’s real research on that too, not just anecdote.

The menopause transition carries a measurable, elevated risk of depression and anxiety, independent of whatever else is happening in your life. A Lancet series on mental health across the menopause transition found that women with a prior history of depression face up to a 2.67-fold increased risk of a depressive episode recurring during the transition, and a broader pattern across multiple cohort studies shows that perimenopause itself is a window of heightened vulnerability, driven by hormone fluctuation rather than just circumstance (Lancet, 2024). Brain fog, mood swings, and anxiety that shows up for no obvious reason are not signs you’re falling apart. They’re a documented, physiological part of what’s happening, and they’re also exactly the symptoms most likely to get you dismissed if a clinician doesn’t have the training to recognize them for what they are.

That combination, real symptoms plus a system unequipped to name them, does something specific to a person’s sense of their own reliability. You stop trusting your own read on what’s happening in your body, because you’ve been told often enough that it’s probably nothing, or stress, or just aging. That’s not a failure of resilience. It’s what happens when the information you need to make sense of your own experience simply isn’t being handed to you by the people whose job it is to hand it to you.

What the article actually says about why

Strip it back, and there are five failures stacked on each other.

1. A generation of doctors stopped using hormone therapy because of a single headline in 2002. That year, the Women’s Health Initiative trial found a rise in breast cancer for women who started combined estrogen and progestin therapy in their sixties. News coverage missed the details. Eighteen years later, follow-up research showed there was no difference in overall deaths between hormone therapy and placebo (Manson et al., JAMA, 2017). The Menopause Society’s 2022 statement is clear: hormone therapy works best for hot flashes and night sweats, helps protect bones, and is usually worth it for women under sixty or within ten years of menopause (Menopause, 2022;29(7):767–794). The science has changed, but training hasn’t kept up. Around 41% of Canadian medical schools still leave out menopause entirely (FP Analytics / Bayer, 2025).

2. Gynecology isn’t required in Canadian primary care training. Family doctors who care about women’s health usually end up in obstetrics because it pays more. Menopause counselling takes time, and fee-for-service punishes anything that takes too long.

3. Most provinces don’t have a billing code for group education or for new care models that could let one specialist help many people at once. Dr. Leyland wants this to change. He’s called for group visits and for doctors to be paid for education and prevention, not just for quick visits. Manitoba leads the way with its menopause-specific fee codes. The SOGC has asked the rest of Canada to catch up.

4. The care gap has created a two-tier system. Some private clinics are excellent, run by doctors who left public practice to build something better. These clinics often have long waitlists anyway. Dr. Carly Jacobson, who started a private clinic after years in public practice, said her waitlist was two and a half years until she managed to cut it down by one year. Some clinics aren’t as careful, and oversight in the private sector is weak, even as marketing budgets grow. Dr. Leyland says two-tier care is unavoidable, since so much of Canadian health care is already outside full public coverage. He doesn’t think banning private care is realistic. That trade-off is uncomfortable but real.

5. At the root: none of this would have been allowed to pile up if it had affected men’s health. A 2026 report for the Senate committee on Bill S-243 found that closing the women’s health gap could add $37 billion a year to Canada’s economy (McKinsey Health Institute, cited in SOGC Senate brief, 2026). International research shows the same trend. One large Scandinavian study found that a menopause diagnosis means lower earnings, more lost jobs, and greater need for social support, especially for women already at a disadvantage (Conti, Ginja, Persson & Willage, National Bureau of Economic Research, 2025).

Senator Danièle Henkel’s Bill S-243, the National Framework for Women’s Health in Canada Act, is working its way through the Senate right now. It’s a broader bill than menopause alone, covering conditions from endometriosis to cardiovascular disease, but menopause and perimenopause care are named explicitly among the gaps it’s meant to address. It was referred to the Standing Senate Committee on Social Affairs, Science and Technology in March 2026 (bill status, LEGISinfo). Dr. Gunter has floated the idea of a federal “women’s health czar” to keep this kind of momentum from stalling. It’s a slow process either way. It’s also the right one, and it’s worth watching.

What you can do this week, whether or not you ever hear of us

The system will take years to change. You’re in menopause now. So the honest question isn’t “when will the system fix this?”; it’s “what can I do this week?” None of what follows requires signing up for anything.

Get organized before the appointment. The single most useful thing you can walk in with is a symptom picture your doctor can read in ninety seconds. Most appointments that go sideways go sideways because there wasn’t time to establish what was happening. If you can hand over a one-page summary of what’s changed, when it started, how it’s affecting sleep, work and mood, and what you’ve already tried, you’ve bought back the ten minutes the fee code doesn’t cover. Nila’s weekly check-in and symptom tracker can build that picture over time and export it as a doctor-ready summary.

Ask specifically for a menopause-trained clinician. The Menopause Society (formerly NAMS) maintains a certified practitioner directory. So does the Canadian Menopause Society. Plenty of good doctors aren’t on either list, but every doctor who is has actively opted in to training their medical school didn’t require. That’s a meaningful signal. Nila’s practitioner directory also flags menopause-trained clinicians, with member notes on who has actually been helpful.

Know what a second opinion is for. A first appointment that didn’t get you what you needed is data. What you’re looking for on the second one is a different level of familiarity with current hormone therapy prescribing.

If you’re paying privately, ask sharper questions. Some private menopause clinics give really good care. Many doctors moved there after getting frustrated with the public system, not just to make money, and even these clinics have long wait lists. If you’re paying for care, go ahead and ask: Does the doctor have specialized training in menopause? Will you get prescriptions based on solid research? Is follow-up included? Are there any business ties you should know about? A good clinic will answer all that clearly.

If you’re not sure where BC’s new coverage or any provincial program leaves you, our page on MHT coverage across Canada tracks what’s actually covered where, province by province, and we update it as things change rather than leaving it to go stale.

Use Nila’s research library and community if you want context that doesn’t require an appointment. Our research library is evidence-graded and dated, and our community is moderated by people who’ve been through it. Sometimes the right next step is just knowing you’re not the only one trying to figure this out.

Add your Canadian voice, and read what 13,000 women already said

One of the few genuinely national efforts to gather Canadian patient experience is MenopauseAndU, an SOGC-affiliated site whose "We Hear You" one-pagers were built from more than 13,000 survey responses from women across the country (SOGC MenopauseAndU, 2024). The one-pagers cover what women wish their partners, workplaces, families and clinicians understood, and they're free to download and hand to anyone in your life who needs the short version.

The same team is still collecting responses through their Perimenopause and Menopause Well-being Survey. If you've been through it and want your experience counted in the next round of Canadian data, that's the door. It takes about ten minutes.

If you'd rather watch than read, their Feb 24, 2026 Menopause 101 forum with Drs. Jacobson, Evaniuk and Brennan and the follow-up Q&A PDF are both open access. It's a good primer if you're bringing a partner or parent along on this.

The line we’re trying to draw

We built a page for exactly the stretch this article is about: the space between noticing something’s wrong and actually getting seen. Not because we think a website is a substitute for the specialist care Dr. Leyland is describing, but because that space is real, most people spend years in it, and almost nothing is built specifically for it.

We’re not a clinic, and we’re careful about that. We don’t prescribe or diagnose. We built what I kept wishing I had, somewhere to get your bearings while you wait and the words you need for your next appointment.

So we pulled together a research library you can trust, a symptom guide that covers more than just hot flashes, a directory of doctors who’ve chosen to learn about menopause, and a community that stays useful because it’s closely watched. We’re not here to replace your doctor. We just want to help you make the most of the short time you get when you finally see one.

We’re also making sure nobody’s left out: trans women, Black women (who often start menopause earlier and have symptoms longer), neurodivergent folks, and people whose menopause came from surgery, chemo, or medicine, not just age. When we say every body’s welcome, we mean it. We don’t get to decide who counts; you do.

The gap the Medscape piece describes is a systems problem, and it needs a systems solution: mandatory menopause training in medical schools, capitation instead of fee-for-service where that fits, billing codes that reward prevention and education, real oversight of the private sector, and the kind of national coordination Bill S-243 is trying to establish. We can’t do any of that. No website or company can. What we can do is help you through the years you’re stuck waiting, without pretending that’s a real fix for a broken system.

If you want to raise your voice on Bill S-243, the bill’s status page tells you where it is in the Senate. Writing to your senator isn’t symbolic. It’s one of the specific things Dr. Gunter and Dr. Leyland both said is needed.

References

Avis, N. E., Crawford, S. L., Greendale, G., Bromberger, J. T., Everson-Rose, S. A., Gold, E. B., Hess, R., Joffe, H., Kravitz, H. M., Tepper, P. G., & Thurston, R. C. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine, 175(4), 531–539. https://doi.org/10.1001/jamainternmed.2014.8063

BC Women’s Health Foundation. (2026). Midlife women’s health. https://bcwomensfoundation.org/midlife-health/

BC Women’s Hospital + Health Centre. (n.d.). Menopause. Retrieved July 9, 2026, from https://www.bcwomens.ca/health-info/staying-healthy/menopause

Brotto, L. A., Fisher, S., Yakubu, T., Santana Parrilla, J., & Prestley, N. (2026). Better aging in BC: Mapping menopause research priorities. Women’s Health Research Institute. https://whri.org/wp-content/uploads/2026/06/Mapping-Menopause-Report-June-18-2026.pdf

Conti, G., Ginja, R., Persson, P., & Willage, B. (2025). The menopause “penalty” (NBER Working Paper No. 33621). National Bureau of Economic Research. https://www.nber.org/papers/w33621

FP Analytics, & Bayer. (2025). The health and economic impacts of menopause: Canada case study. https://impactsofmenopause.com/bayer-fpa/case-study-canada/

Government of British Columbia. (2025, July 4). Western Canada’s first menopause clinic supports more people in B.C. [Press release]. https://news.gov.bc.ca/releases/2025HLTH0066-000644

Greene, J. G. (1998). Constructing a standard climacteric scale. Maturitas, 29(1), 25–31. https://doi.org/10.1016/S0378-5122(98)00025-5

Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10. Journal of Clinical Endocrinology & Metabolism, 97(4), 1159–1168.

Heinemann, K., Ruebig, A., Potthoff, P., Schneider, H. P. G., Strelow, F., Heinemann, L. A. J., & Do Minh, T. (2004). The Menopause Rating Scale (MRS): Reliability of scores of menopausal complaints. Health and Quality of Life Outcomes, 2, 45. https://doi.org/10.1186/1477-7525-2-45

Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Chlebowski, R. T., Howard, B. V., Thomson, C. A., Margolis, K. L., Lewis, C. E., Stefanick, M. L., Jackson, R. D., Johnson, K. C., Martin, L. W., Shumaker, S. A., Espeland, M. A., & Wactawski-Wende, J. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women’s Health Initiative randomized trials. JAMA, 318(10), 927–938. https://doi.org/10.1001/jama.2017.11217

Medscape News Canada. (2026, July 9). Lack of menopause care in Canada reflects systemic issues. Medscape. https://www.medscape.com/viewarticle/lack-menopause-care-canada-reflects-systemic-issues-2026a1000n25

Medscape News Canada. (2026). Menopausal women in Canada face multiple barriers to care. Medscape. https://www.medscape.com/viewarticle/menopausal-women-canada-face-multiple-barriers-care-2026a1000big

Parliament of Canada. (n.d.). Bill S-243, National Framework for Women’s Health in Canada Act. LEGISinfo. Retrieved July 9, 2026, from https://www.parl.ca/legisinfo/en/bill/45-1/s-243

Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A., Howard, B. V., Johnson, K. C., Kotchen, J. M., & Ockene, J. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288(3), 321–333. https://doi.org/10.1001/jama.288.3.321

Society of Obstetricians and Gynecologists of Canada. (2026, May 12). Brief to the Standing Senate Committee on Social Affairs, Science and Technology on Bill S-243. https://sencanada.ca/Content/Sen/Committee/451/SOCI/briefs/2026-05-12_SOCI_S-243_Brief_SOGC_e.pdf

Society of Obstetricians and Gynecologists of Canada. (2024). MenopauseAndU: We hear you — patient one-pagers and well-being survey. https://www.menopauseandu.ca/

The 2022 hormone therapy position statement of The North American Menopause Society Advisory Panel. (2022). Society of Obstetricians and Gynecologists of Canada. (2024). MenopauseAndU: We hear you — patient one-pagers and well-being survey. https://www.menopauseandu.ca/

The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028